Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs Tempus AI — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $117.32, while Tempus AI trades at $47.17 (market cap $8.80B). The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| QQQE | TEM | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $122.72 | $103.25 |
52-Week Low | $96.06 | $42.37 |
Market Cap | — | $8.80B |
Enterprise Value | — | $9.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE trades at $116.70, down 0.09% on the day, with a mixed technical signal showing a bullish overall trend but bearish moving averages. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to cap-weighted peers. Recent news highlights its appeal as a diversified alternative amid high market concentration, with SpaceX's upcoming Nasdaq-100 inclusion potentially driving passive inflows.
The outlook for QQQE is positive due to its defensive structure and uncorrelated performance, though technical indicators suggest near-term consolidation. Key risks include market volatility and reliance on growth stocks. Analyst sentiment is constructive, emphasizing its role in balanced Nasdaq exposure.
Tempus AI (TEM) trades at $48.41, down 7.74% amid market reaction to its $1.5 billion acquisition of Personalis. The stock shows bearish technical signals with negative moving averages and oversold RSI levels. Fundamentally, the company maintains strong revenue growth ($1.27B in 2025) but faces significant losses (-$245M net income) and negative margins. Recent news highlights strategic expansion in cancer diagnostics through AI-driven platforms.
Despite analyst optimism (61.5% buy ratings, $68.50 target), TEM faces execution risks from the major acquisition and persistent profitability challenges. The stock's current discount to target offers potential upside if integration succeeds, but high cash burn and competitive pressures require careful monitoring for investors considering entry at these levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
